Udho Thadani, M.D., commented that heart failure patients already have a rather full plate just with today's standard medications, which include a b-blocker, an ACE inhibitor or angiotensin receptor blocker, an aldosterone blocker such as spironolactone, and digoxin.
If even a few of the drugs with novel mechanisms of action that are in the developmental pipeline eventually find their way into routine clinical practice on top of today's standard therapy, compliance issues will become a much more prominent concern, predicted Dr. Thadani, professor emeritus of medicine at the University of Oklahoma, Oklahoma City.